Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more
Jade Biosciences, Inc. (JBIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.123x
Based on the latest financial reports, Jade Biosciences, Inc. (JBIO) has a cash flow conversion efficiency ratio of -0.123x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.12 Million) by net assets ($179.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jade Biosciences, Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Jade Biosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jade Biosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jade Biosciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Akwel SA
PA:AKW
|
0.048x |
|
Mortech Corporation
TWO:7419
|
-0.031x |
|
Aldeyra The
NASDAQ:ALDX
|
-0.143x |
|
Ezwelfare Co Ltd
KQ:090850
|
0.020x |
|
Soechi Lines Tbk
JK:SOCI
|
0.031x |
|
Waldencast Acquisition Corp
NASDAQ:WALD
|
-0.021x |
|
Nien Hsing Textile Co Ltd
TW:1451
|
0.022x |
|
Log-In Logística Intermodal S.A
SA:LOGN3
|
-0.202x |
Annual Cash Flow Conversion Efficiency for Jade Biosciences, Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Jade Biosciences, Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.43 Million | $-71.20 Million | -0.931x | -79.57% |
| 2023-12-31 | $109.46 Million | $-56.78 Million | -0.519x | -68.05% |
| 2022-12-31 | $126.74 Million | $-39.12 Million | -0.309x | -94.24% |
| 2021-12-31 | $172.42 Million | $-27.40 Million | -0.159x | +94.05% |
| 2020-12-31 | $2.94 Million | $-7.86 Million | -2.672x | -- |